Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial

This post-approval, open-label trial (n = 1266) assessed the efficacy of efalizumab, administered in accordance with the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Katsambas, Andreas, Peris, Ketty, Vena, Gino, Freidmann, Peter, Wozel, Gottfried, Daudén, Esteban, Licu, Daiana, Placchi, Mauro, De La Brassinne, Michel
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Inc 2009
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805869/
https://ncbi.nlm.nih.gov/pubmed/20098509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1753-5174.2009.00023.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados